Quarterly report [Sections 13 or 15(d)]

Significant Strategic Collaborations (Details Narrative)

v3.26.3
Significant Strategic Collaborations (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended 33 Months Ended 42 Months Ended 51 Months Ended
Sep. 01, 2026
Mar. 02, 2026
Nov. 02, 2025
May 02, 2025
Nov. 02, 2024
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2026
Sep. 30, 2026
Dec. 31, 2025
Mar. 17, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Revenue           $ 725,257 $ 1,026,957 $ 2,192,781 $ 2,210,115          
Prepaid expense and other assets, current           194,055   194,055   $ 194,055 $ 194,055 $ 194,055 $ 166,294  
Accrued expenses and other current liabilities           496,181   496,181   496,181 496,181 496,181 709,916  
Other noncurrent assets           313,921   313,921   313,921 313,921 313,921 313,921  
Research and development expenses           520,663 756,482 1,734,119 2,292,068          
Catalent [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Payment for services                       3,000,000.0    
Prepaid expense and other assets, current           28,000   28,000   28,000 28,000 28,000 28,000  
Accrued expenses and other current liabilities           100,000   100,000   100,000 100,000 100,000 100,000  
Other noncurrent assets           300,000   300,000   300,000 300,000 300,000 300,000  
Scripps Research [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Accrued expenses and other current liabilities           100,000   100,000   100,000 100,000 100,000 200,000  
Contractual obligation                           $ 900,000
Increase in contractual liabilitiy $ 500,000 $ 500,000 $ 300,000 $ 400,000 $ 400,000                  
Research and development expenses                     2,600,000      
UVA [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Accrued expenses and other current liabilities           0   0   0 $ 0 $ 0 $ 31,000  
Research and development expenses                   $ 600,000        
Royalty Revenue [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Revenue           $ 725,257 $ 1,026,957 $ 2,192,781 $ 2,210,115